{{위키데이터 속성 추적}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 464366483
| image = Cortisol3.svg
| width = 225
| alt =
| image2 = Cortisol-3D-balls.png
| alt2 =

<!--Clinical data -->
| Drugs.com = {{drugs.com|monograph|hydrocortisone}}
| tradename = A-hydrocort, Cortef, Solu-cortef, others<ref name=AHFS2016/>
| MedlinePlus = a682206
| DailyMedID = Hydrocortisone
| pregnancy_AU = A
| pregnancy_AU_comment =<ref>{{웹 인용 | title=Prescribing medicines in pregnancy database | website=[[Therapeutic Goods Administration]] (TGA) | url=https://www.tga.gov.au/prescribing-medicines-pregnancy-database | access-date=21 February 2021 | archive-date=2016-12-20 | archive-url=https://web.archive.org/web/20161220210434/https://www.tga.gov.au/prescribing-medicines-pregnancy-database | url-status= }}</ref>
| class = [[Corticosteroid]]; [[Glucocorticoid]]; [[Mineralocorticoid]]
| routes_of_administration = [[Oral administration|By mouth]] ([[tablet (pharmacy)|tablets]]), [[intravenous administration|intravenous]], [[topical medication|topical]], [[rectal administration|rectal]]
| ATC_prefix = A01
| ATC_suffix = AC03
| ATC_supplemental = {{ATC|A07|EA02}}, {{ATC|C05|AA01}}, {{ATC|D07|AA02}}, {{ATC|H02|AB09}}, {{ATC|S01|BA02}}, {{ATC|S02|BA01}}

<!-- Legal status -->
| legal_AU = S4
| legal_AU_comment = /&nbsp;S3&nbsp;/&nbsp;S2
| legal_BR          = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment  =
| legal_CA          = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment  =
| legal_DE          = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment  =
| legal_NZ          = <!-- Class A, B, C -->
| legal_NZ_comment  =
| legal_UK = POM
| legal_UK_comment = /&nbsp;P&nbsp;/&nbsp;GSL
| legal_US = OTC
| legal_US_comment = /&nbsp;Rx-only<ref>{{웹 인용|url=https://s3.amazonaws.com/archives.federalregister.gov/issue_slice/1991/8/30/43023-43026.pdf#page=3 |title=Hydrocortisone Notice of enforcement policy |publisher=FDA|format=PDF |access-date=31 December 2022}}</ref><ref>{{웹 인용| title=Ala-cort- hydrocortisone cream | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de000081-a245-4f6b-9e7c-e47d84b82338 | access-date=21 February 2021}}</ref><ref>{{웹 인용| title=Ala-scalp- hydrocortisone lotion | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ecba1d44-33a9-44d7-ad06-13ada2375c72 | access-date=21 February 2021}}</ref><ref>{{웹 인용| title=Alkindi Sprinkle- hydrocortisone granule | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26c13a5f-7119-4c6a-bf10-fda4e07d7682 | access-date=21 February 2021}}</ref><ref>{{웹 인용| title=Anusol HC- hydrocortisone acetate suppository | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a562f3d7-2692-4357-aade-ae50afcbfddd | access-date=21 February 2021}}</ref><ref>{{웹 인용| title=Cortef- hydrocortisone tablet | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ce19944-dd88-4a7b-84ca-b07f4ec23bad | access-date=21 February 2021}}</ref>
| legal_EU          = OTC
| legal_EU_comment  = /&nbsp;Rx-only<ref name="Efmody EPAR">{{웹 인용| title=Efmody EPAR | website=[[European Medicines Agency]] (EMA) | date=24 March 2021 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/efmody | access-date=14 June 2021}} Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref><ref>{{웹 인용| title=Efmody Product information | website=Union Register of medicinal products | url=https://ec.europa.eu/health/documents/community-register/html/h1549.htm | access-date=3 March 2023}}</ref>
| legal_UN          = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment  =
| legal_status      = <!-- For countries not listed above -->

<!-- Pharmacokinetic data -->
| bioavailability   = [[Oral administration|Oral]]: 96 ± 20%<ref name="pmid15634032" /><ref name="pmid18611115" />
| protein_bound     = 92 ± 2% (92–93%)<ref name="pmid15634032" /><ref name="pmid18611115" />
| metabolism        = {{Abbrlink|11β-HSDs|11β-Hydroxysteroid dehydrogenases}}, others<ref name="pmid18611115" />
| metabolites       = [[Cortisone]], others<ref name="pmid18611115" />
| onset             = 
| elimination_half-life = 1.2–2.0 hours<ref name="pmid15634032">{{저널 인용| vauthors = Czock D, Keller F, Rasche FM, Häussler U | title = Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids | journal = Clinical Pharmacokinetics | volume = 44 | issue = 1 | pages = 61–98 | date = 2005 | pmid = 15634032 | doi = 10.2165/00003088-200544010-00003 | s2cid = 24458998 }}</ref><ref name="pmid18611115">{{저널 인용| vauthors = Lennernäs H, Skrtic S, Johannsson G | title = Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors | journal = Expert Opinion on Drug Metabolism & Toxicology | volume = 4 | issue = 6 | pages = 749–758 | date = June 2008 | pmid = 18611115 | doi = 10.1517/17425255.4.6.749 | name-list-style = vanc | s2cid = 73248541 }}</ref>
| duration_of_action = 
| excretion         = 

<!--Identifiers -->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 50-23-7
| PubChem = 5754
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00741
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5551
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = WI4X0X7BPJ
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00088
| KEGG2_Ref = {{keggcite|correct|kegg}}
| KEGG2 = D00165
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 17650
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 389621
| synonyms = Cortisol; 11β,17α,21-Trihydroxypregn-4-ene-3,20-dione; 11β,17α,21-Trihydroxyprogesterone

<!--Chemical data -->
| IUPAC_name = (8''S'',9''S'',10''R'',11''S'',13''S'',14''S'',17''R'')-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1''H''-cyclopenta[''a'']phenanthren-3-one
| C=21 | H=30 | O=5
| SMILES = O=C4\C=C2/[C@]([C@H]1[C@@H](O)C[C@@]3([C@@](O)(C(=O)CO)CC[C@H]3[C@@H]1CC2)C)(C)CC4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JYGXADMDTFJGBT-VWUMJDOOSA-N
}}
'''히드로코르티손''' 또는 '''하이드로코르티손'''은 약물로 공급될 때 호르몬 코르티솔의 이름이다. 용도에는 부신피질 부전, 부신생식기 증후군, 고혈당 칼슘, 갑상선염, 류마티스 관절염, 피부염, 천식 및 COPD와 같은 상태가 포함된다. 부신 피질 기능 부전에 대한 선택 치료이다. 경구, 국소 또는 주사로 투여할 수 있다. 장기간 사용 후 치료를 중단하는 것은 천천히 이루어져야 한다.

부작용으로는 기분 변화, 감염 위험 증가, 부종(부기) 등이 있다. 장기간 사용 시 흔한 부작용으로는 골다공증, 배탈, 신체적 쇠약, 쉽게 멍이 들기 쉬움, 칸디다증(효모 감염) 등이 있다. 임신 중에 사용하기에 안전한지는 확실하지 않다. 하이드로코르티손은 글루코코르티코이드이며 항염증 및 면역 억제 작용을 한다.

히드로코르티손은 1936년에 특허를 받았고 1941년에 의료용으로 승인되었다. 세계보건기구의 필수 의약품 목록에 나열되어 있다. 제네릭 의약품으로 이용 가능하다. 2020년에는 미국에서 149번째로 가장 많이 처방된 약물로 300만 건 이상의 처방이 있었다.

== 외부 링크 ==
* {{웹 인용| url = https://druginfo.nlm.nih.gov/drugportal/name/hydrocortisone | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Hydrocortisone }}

[[분류:알코올]]
[[분류:당질 코르티코이드]]
[[분류:케톤]]
[[분류:무기질코르티코이드]]
[[분류:희귀약]]
[[분류:프레그난]]
[[분류:세계 보건 기구 필수 의약품]]